Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma

Li Tian1,2*, Xiao-Fei Lv1,2*, Jun-Dong1,2, Jian Zhou1,2, Yu Zhang1,3, Shao-Yan Xi1,3, Rong Zhang1,2, Chuan-Miao Xie1,2

1Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangzhou, P. R. China; 2Department of Imaging Diagnosis Center, Cancer Center, Sun Yat-sen University, Guangzhou, P. R. China; 3Department of Pathology, Cancer Center, Sun Yat-sen University, Guangzhou, P. R. China.

*Equal contributors.

Received July 5, 2015; Accepted September 6, 2015; Epub September 15, 2015; Published September 30, 2015

Abstract: To retrospectively review the clinical features and computed tomography (CT) and magnetic resonance imaging (MRI) findings of PAAC so as to improve the accuracy of imaging diagnosis. Seventeen patients with pathologically proven PAAC were enrolled. Their clinical and imaging findings were retrospectively reviewed. The median age of the patients was 56 years (range, 7-74 years). The tumors were located in any part of the pancreas or exophytic growth, with a median maximal diameter of 68 mm. Thirteen masses presented with ovoid shape. Nine masses had less clear boundaries. Eleven masses showed a variable degree of intratumoral hypodense or necrosis before contrast administration on CT images. Five masses showed hypointense on unenhanced T1 weighted images and hyperintense on T2 weighted images. After contrast administration, the most common enhancement pattern was slight enhancement on arterial phase and persistent enhancement on portal vein phase. Infiltration of tumor into duct and vessels was not common. Five and 2 patients developed hepatic metastasis and local lymphadenopathy, respectively. By the end of the last follow-up, 11 patients survived free of disease. PAAC should be included in the differential diagnosis when a bulky, ovoid, heterogeneous mass, with clear or less clear margins, in the pancreas or peripancreas, with slight and persistent enhancement after contrast administration on CT or MRI images is seen, particularly in elder men.

Keywords: Pancreatic acinar cell carcinoma, clinical feature, computed tomography, magnetic resonance imaging

Introduction

Pancreatic acinar cell carcinoma (PACC) is a rare malignant epithelial neoplasm that exhibits exocrine enzyme production by neoplastic cells and accounts for only 1% of all pancreatic neoplasms, although pancreatic acinar cells represent more than 80% of pancreatic tissue [1-5]. With few exceptions, acinar cell carcinoma occurs during the fifth to seventh decades of life and has a male predominance. PACC usually manifests nonspecific symptoms and signs, such as abdominal pain, weight loss, and abdominal mass; jaundice is less frequent compared with pancreatic ductal adenocarcinoma (DAC). “Schmid’s triad”, a syndrome of subcutaneous fat necrosis, polyarthralgia, and eosinophilia due to increased serum lipase, is typical but very rare in PACC [1].
Radiological findings of pancreatic acinar cell carcinoma

Table 1. The clinical features of 17 patients with PACCs

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age</th>
<th>Symptoms</th>
<th>Laboratory test</th>
<th>Treatment</th>
<th>Follow up</th>
<th>FD (month)</th>
<th>Recurrence</th>
<th>Metastasis</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>54</td>
<td>AP</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>5.6</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>62</td>
<td>AP</td>
<td>Amylase↑*</td>
<td>WE+CT</td>
<td></td>
<td>3.6</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>53</td>
<td>AP</td>
<td>AFP↑</td>
<td>WE</td>
<td></td>
<td>11.5</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>53</td>
<td>AP</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>76.2</td>
<td>N</td>
<td>HM</td>
<td>PD</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>13</td>
<td>J</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>12.8</td>
<td>N</td>
<td>HM/LM</td>
<td>PD (death)</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>65</td>
<td>AP</td>
<td>Ne</td>
<td>WE</td>
<td></td>
<td>55.8</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>7</td>
<td>Male</td>
<td>61</td>
<td>AP</td>
<td>Ne</td>
<td>WE</td>
<td></td>
<td>32.9</td>
<td>N</td>
<td>HM</td>
<td>PD (death)</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>72</td>
<td>AP</td>
<td>Ne</td>
<td>WE</td>
<td></td>
<td>10.2</td>
<td>N</td>
<td>LM</td>
<td>PD (death)</td>
</tr>
<tr>
<td>9</td>
<td>Male</td>
<td>40</td>
<td>AP</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>54.4</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>74</td>
<td>AP</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>35.6</td>
<td>N</td>
<td>HM</td>
<td>PD (death)</td>
</tr>
<tr>
<td>11</td>
<td>Male</td>
<td>59</td>
<td>AP</td>
<td>CA199↑</td>
<td>WE+CT</td>
<td></td>
<td>9.7</td>
<td>N</td>
<td>HM</td>
<td>PD (death)</td>
</tr>
<tr>
<td>12</td>
<td>Male</td>
<td>56</td>
<td>NC</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>120.1</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>13</td>
<td>Male</td>
<td>73</td>
<td>AP</td>
<td>CEA↑</td>
<td>WE+CT</td>
<td></td>
<td>17.0</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>14</td>
<td>Male</td>
<td>15</td>
<td>AP</td>
<td>AFP↑</td>
<td>WE+CT</td>
<td></td>
<td>87.5</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>15</td>
<td>Male</td>
<td>60</td>
<td>NC</td>
<td>Ne</td>
<td>WE+CT</td>
<td></td>
<td>3.0</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>16</td>
<td>Female</td>
<td>7</td>
<td>AP</td>
<td>Amylase↑</td>
<td>WE+CT</td>
<td></td>
<td>20.0</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
<tr>
<td>17</td>
<td>Male</td>
<td>51</td>
<td>NC</td>
<td>Ne</td>
<td>WE</td>
<td></td>
<td>16.4</td>
<td>N</td>
<td>N</td>
<td>CR</td>
</tr>
</tbody>
</table>

Note: AP = abdominal pain; J = jaundice; NC = no complaints; Ne = negative; AFP = Alpha Fetal Protein; CA199 = Carbohydrate Antigen 199; CEA = Carcino Embryonic Antigen; WE = wide excision; CT = chemotherapy; FD = follow-up duration; N = No; HM = hepatic metastasis; LM = lymphatic metastasis; CR = complete response; PD = progressive disease. *: the symbol "↑" denotes elevated tumor marker levels.

(MRI), of a series of pathologically confirmed PACC to improve the recognition of this disease and accuracy of imaging diagnosis.

Material and methods

Patient population

This retrospective study was approved by the institutional review board, and the requirement to obtain informed consent was waived. We performed a comprehensive retrospective review of the medical records of patients with pathologically confirmed PACC treated at our cancer center between January 2005 and January 2015. We reviewed the clinical data, CT and MRI images, as well as follow-up outcome. In total, 17 patients (twelve men and five women; median age, 56 years, range 7-74 years) were enrolled.

Imaging protocol and radiological evaluation

Twelve patients underwent a CT scan, three patients underwent an MR scan, two patients underwent a CT and MR scan sequentially.

The CT scans were performed with a Toshiba Aquilion TM64 (Toshiba Medical Systems, Otawara, Japan) helical CT system. The main imaging parameters were as follows: 5-mm section thickness reconstructions, 25-cm field of view, 120-kV tube voltage, 300-mA current, and a 512 × 512 matrix. An intravenous bolus dose of 100 ml of a non-ionic iodinated contrast agent (iopromide; Ultravist, Bayer Schering Pharma AG, Berlin, Germany) was administered at a rate of 2.5 ml/s.

The MR scans were performed using a 1.5-T system (Signa CV/i; GE Healthcare, Chalfont St Giles, UK). The patients were placed in a supine position, and a body coil was used. T1-weighted, fast spin-echo images in the axial and coronal planes (400-500/10-20), T2-weighted fast spin-echo MR images in the axial and coronal plane and T2-weighted, fat-suppressed, fast spin-echo in the axial and coronal planes (4000-5000/95-110) were obtained prior to injection of contrast material. After an intravenous administration of 0.1 mmol/kg body weight of gadopentetate dimeglumine (Magnevist; Bayer Schering Pharma AG, Berlin, Germany), the axial T1-weighted spin-echo sequence and axial and coronal T1-weighted, fat-suppressed, spin-echo sequences were performed sequentially using the same parameters applied prior to the injection of gadopen-
Radiological findings of pancreatic acinar cell carcinoma

For imaging in the axial plane, a 5-mm section thickness with a 1-mm intersection gap was used. For imaging in the coronal planes, a 6-mm section thickness with a 1-mm intersection gap was used. The image matrix was 512 × 512, and the field of view was 32 cm.

All images were re-evaluated by two radiologists with more than 10 years of experience in radiological evaluation of abdominal tumors and disputes were resolved in consensus. The following findings were analyzed: (1) lesion location (the head, neck, body or tail of the pancreas or exophytic growth), (2) shape and margins, (3) tumor size (largest diameter), (4) density/signal intensity, (5) enhancement pattern, (6) presence of calcification or hemorrhage, (7) obstruction of pancreatic ductal (>3 mm) or biliary ductal (>8 mm), (8) encasement of adjacent vessels, (9) presence of distant metastatic disease, and (10) presence of peripancreatic lymphadenopathy.

Pathological examination and analysis

All masses were surgically resected within one week after CT/MR examination, and 2 pathologists reviewed the gross appearance of the tumor specimens and hematoxylin and eosin (H&E)-stained sections. Immunohistochemical analysis (IHC) was performed, including anti-alpha 1 antitrypsin (AAT), chymotrypsin, chromogranin A (CgA), synaptophysin (Syn), cytokeratin (CK), vimentin, neuron-specific enolase (NSE), epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA) and insulin. The tissue samples of two masses were stained with diastase digestion periodic acid-Schiff (PAS) to confirm the presence of dPAS-positive granules in the cytoplasm.

Treatment and follow-up

In addition to surgical treatment, some patients received adjuvant chemotherapy. The follow-up period was estimated from the first day of treatment to the day of death or day of the last examination.

Results

The clinical features of the 17 patients are summarized in Table 1. Thirteen patients were older than 50 years (13/17, 76.5%), and there...
Radiological findings of pancreatic acinar cell carcinoma

was an obvious male preponderance in our series (12/17, 70.6%). The majority of patients complained of abdominal pain. Four patients had slightly elevated tumor marker levels, and two had slightly elevated amylase levels. The remaining 11 patients had negative laboratory results. Wide resection of the masses, including resection of pancreatic body and/or tail with or without splenectomy and Whipple procedure, followed by adjuvant chemotherapy, was the main treatment regimen. After 3.0 to 120.1 months of follow-up, 6 patients had metastatic disease, and none developed local recurrence. Five patients died of tumor metastasis, one

Figure 1. A 54-year-old male with ACC in the body and tail of the pancreas. A. Unenhanced axial CT image showed an ovoid and well-circumscribed mass in the body and tail of the pancreas, with roughly uniform density. B. The mass revealed mild enhancement in the arterial phase when compared to the normal pancreas. C. The mass showed persistent enhancement in the portal vein phase.

Figure 2. A 15-year-old male with ACC in the body and tail of the pancreas. A. Unenhanced axial CT image showed an ill-circumscribed mass in the body and tail of the pancreas with irregular shape. Strip-shaped calcification was found in it. B. The mass revealed intense enhancement in the arterial phase compared with the pancreatic tissue. C. The contrast agent in the mass washed out in the portal vein phase.

Figure 3. A 53-year-old male with an exophytic ACC. A. Coronal T1 weighted MR image demonstrated an exophytic mass in the left peritoneal cavity, with ovoid shape and clear margin. The mass had a hypointense signal. B. The mass had a heterogeneous, hyperintense signal on the fat-suppressed T2 weighted MR image. C. The mass presented mild enhancement on the fat-suppressed and enhanced T1 weighted MR image in the arterial phase. D. The mass showed persistent enhancement in the portal vein phase.
Radiological findings of pancreatic acinar cell carcinoma

The CT and MRI findings of the 17 patients are summarized in Table 2. The tumors were located in the body and tail of the pancreas (n=5, Figures 1, 2), the tail of the pancreas (n=3), the head of the pancreas (n=2), the head and neck of the pancreas (n=2), the neck of the pancreas (n=1) and exophytic growth (n=4, Figure 3). The maximum diameters of these masses ranged from 28 to 140 mm, with a median maximum diameter of 68 mm. The masses had an ovoid shape (n=13, Figure 1) or irregular shape (n=4, Figure 2). Eight and 9 masses had clear (Figure 1) and less clear margins (Figure 2), respectively. Eleven of the fourteen masses detected by CT examination presented with a variable degree of intratumoral hypodensity or necrosis before contrast administration (Figure 4A). All of the 5 masses detected by MR examination displayed hypointensity on unenhanced T1-weighted images and hyperintensity on T2-weighted images compared with normal pancreatic parenchyma (Figure 3A, 3B). After contrast administration, the most common enhancement pattern was slight enhancement in the arterial phase and persistent enhancement in the portal vein phase compared with pancreatic parenchyma (7/17, 41.2%) (Figures 1B, 1C, 3C, 3D). Then, a pattern of moderate or intense enhancement in the arterial phase and washout in the portal vein phase was observed (4/17, 4/17, 23.5%, respectively, Figures 2B, 2C, 4B, 4C). Calcification and hemorrhage were detected in only 5 and 3 masses (Figures 2A, 4A), respectively. Bile duct and pancreatic duct dilatation were observed in 1 and 3 patients,
Radiological findings of pancreatic acinar cell carcinoma

Figure 6. Metastasis of the liver and lymph nodes in the patients with ACC. The same patients as that of Figure 5A. The patients developed hepatic and lymphatic metastasis 1 year after operation. Enhanced axial CT image showed the hepatic nodules (black arrows) and the enlarged lymph nodes in the hepatic hilar region and the periphery of vena cava (white arrows).

respectively (Figure 5A, 5B). Four masses had infiltrated the adjacent vessels, including the splenic vein and portal vein (Figure 4D). Five patients developed hepatic metastasis, and 2 patients developed local lymphadenopathy (Figures 4C, 6).

The cut surfaces of the masses were greyish white or dark red in appearance, and patchy hemorrhages were observed in 3 cases. Internal areas of necrosis and cystic change were observed in 14 masses. Histologically, the most common patterns observed in PACC are acinar or solid formations (Figure 7). The IHC analysis results showed that AAT and chymotrypsin were positive in all masses, whereas CgA and Syn were negative or focally slightly positive. dPAS-positive granules were observed in two masses.

Discussion

The 3 main components of the pancreas are the duct (4%), acinar cells (82%) and islet cells (14%). Although acinar cells occupy most of the normal pancreas, PACC is far less common than DAC, which accounts for more than 90% of total pancreatic neoplasms, and islet cell tumors (ICTs) [16, 17]. PACC, also known as pancreatic acinic cell carcinoma and acinous cell carcinoma [18, 19], was first described by Berner in 1908 [20]. The diagnosis of PACC is based on electron microscopic and immunohistochemical studies [21-23]. PACC cells are characteristically arranged in an acinar formation. Immunohistochemical labeling was strongly positive for trypsin, chymotrypsin, lipase and amylase and negative or only focally positive for chromogranin and synaptophysin.

PACC predominantly affects the elderly, with peak incidence in the seventh decade of life, and male patients outnumber female ones [21-23]. In this study, 76.5% of patients were older than 50 years, and 70.6% of patients were male. Our results were generally consistent with those of previous studies.

Clinically, PACC patients commonly show symptoms related to either a local mass effect or metastases [21, 22, 24]. The most common manifestation in our series was abdominal pain. Only one patient (1/17, 5.9%) presented with jaundice, a relative common sign for DAC patients, which was helpful for the differential diagnosis for both diseases. Interestingly, although PACC can present with “lipase hypersecretion syndrome” [25], which is characterized by fever, arthralgia, skin rash, and fat necrosis due to lipase secretion by the tumor into the blood stream, none of our patients exhibited this clinical manifestation. Additionally, none of our patients had elevated lipase levels. However, slightly elevated AFP, CEA, CA19-9 and amylase levels were observed in a small number of patients, which is concordant with other series [26].

Our results revealed that the masses could affect any part of the pancreas and did not show propensity for the pancreatic head, which has been suggested in previous reports [18,
Radiological findings of pancreatic acinar cell carcinoma

In contrast, the masses were evenly distributed in the head/neck and body/tail of the pancreas, which was similar to the results of Raman et al [25]. Four masses were located outside the pancreas, and this characteristic can be used to differentiate PACCs from other pancreatic tumors because it is rare in more common pancreatic neoplasms.

The median maximal diameter of the masses was 68 mm, with a maximum value of 140 mm, which was essentially in agreement with previous reports [24, 27, 28]. Moreover, thirteen masses (76.5%) presented with an ovoid shape, and 8 masses (47.1%) had a clear margin. Tatli et al reported the radiological findings of 11 patients with PACC and found that 90.9% of masses presented with an ovoid shape and well-circumscribed margin [18]. Raman et al [25], Butturini et al [1] and Chiou et al [24] obtained similar results. Our results were somewhat different from those of other studies. We speculate that this might be due to our relatively small sample size.

PACC often presents with varying amounts of intratumoral hypodensity on CT images [9-11, 22, 29]. Indeed, 11 of the 14 masses (84.6%) detected by CT revealed different areas of hypodensity, which might be composed of hypovascular neoplastic tissue or a necrotic portion. One possible explanation for the necrotic portion is the digestive effect of the pancreatic enzymes released by neoplastic cells. This feature is helpful for differentiating PACC from DAC, of which the latter commonly appears solid without significant necrosis [24]. All 5 masses detected by MRI exhibited a slightly hypointense signal on T1-weighted images and a hyperintense signal on T2-weighted images compared with pancreatic parenchyma, which was similar to the previous reports [18, 27] and, this finding is not characteristic compared with most malignant tumors.

After contrast administration, most masses had slight or moderate enhancement compared with the normal pancreas in the arterial phase and persistent enhancement in the portal vein phase. This enhancement pattern could be useful for differentiating PACC from DAC and ICT. The degree of enhancement of PACC is usually higher than that of DAC but poorer than that of ICT in the pancreas in the arterial phase [17, 30, 31]. Nevertheless, PACCs may be radiologically indistinguishable from solid-pseudopapillary tumors (SPT) using enhancement pattern. The only valuable feature is that SPTs predominantly affect young women and usually present with intratumoral hemorrhage [32].

Five and 3 masses presented with calcification and hemorrhage, respectively. Calcification within PACC masses has been mentioned in the literature [10, 33], but the occurrence rate is low. Intratumoral hemorrhage of PACCs has been rarely mentioned. Therefore, the presence of calcification and hemorrhage is not significant for the diagnosis of PACCs.

PACCs originate from acinar cells of the pancreas rather than the ductal epithelium; thus, PACCs rarely induce dilatation of the biliary/pancreatic duct [27]. Bile duct and pancreatic duct dilatation was observed in 1 and 3 patients, respectively. This feature is meaningful for differentiating PACC from DAC, which nearly always results in bile duct and pancreatic duct obstruction. In addition, four masses investigated here exhibited infiltration of adjacent vessels, as mentioned in the literature [25, 28], which was a less common feature of PACC.

PACC can develop local and distant metastases, and the most common metastasis locations are liver and lymph gland. In our study, 5 and 2 patients developed hepatic metastasis and local lymphadenopathy, respectively. However, a better prognosis for PACC than DAC can be achieved with complete tumor resection. Twelve patients in our study survived with or without disease during long-term follow-up, and the survival rate was higher than that of previous reports [34, 35]. Unfortunately, 6 patients had a relatively short follow-up period.

In conclusion, PACC usually affects elder men. Typical CT and MR findings of PACC include a large mass with ovoid shape, clear or less clear margin, patchy hypodensity or necrotic component, with slight and persistent enhancement after contrast administration, and lack of ductal dilatation. After surgical removal, the patients recover well.

Disclosure of conflict of interest

None.
Radiological findings of pancreatic acinar cell carcinoma

Address correspondence to: Drs. Rong Zhang and Chuan-Miao Xie, Department of Imaging Diagnosis Center, Cancer Center, Sun Yat-Sen University, 651 Dongfeng Road, East, Guangzhou 510060, Guangdong, P.R. China. Tel: +86-20-87342125; Fax: +86-20-87342125; E-mail: rongzhangabc@163.com (RZ); Tel: +86-20-87343218; Fax: +86-20-87343218; E-mail: chuanmiaoxieabc@163.com (CMX)

References


Radiological findings of pancreatic acinar cell carcinoma


